ADRB2 and neoplasm: Research indicates that knocking down β2‐AR in MDSCs reverses their immunosuppressive function, enhancing T‐cell proliferation and IFN‐γ production, while knocking down Adrb2 slows tumor growth, reduces programmed death‐ligand 1 (PD‐L1) expression, and lowers serum levels of immunosuppressive cytokines.292